LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over […]

Lugano, Switzerland, January 10, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 9, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 4, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, November 29, 2022 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution […]

Lugano, Switzerland, October 18, 2022 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a diversified pipeline of innovative oncology assets, announces that […]

Lugano, Switzerland, 21 September 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces that two […]

Lugano, Switzerland, September 8, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction […]

Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record […]